Upgrade to SI Premium - Free Trial

Form 4 ANAVEX LIFE SCIENCES For: Sep 24 Filed by: Boenisch Sandra

September 28, 2026 9:37 PM
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Boenisch Sandra
(Last) (First) (Middle)
630 5TH AVENUE, 20TH FLOOR
(Street)
NEW YORK NY 10111
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
PFO & Treasurer
3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 10.09 09/24/2026 A 20,000 09/24/2026 06/27/2032 Common Stock 20,000 $ 0 20,000 (1) D
Stock Option (Right to Buy) $ 8.57 09/24/2026 A 25,000 09/24/2026 03/31/2033 Common Stock 25,000 $ 0 25,000 (1) D
Stock Option (Right to Buy) $ 5.36 09/24/2026 A 25,000 09/24/2026 02/20/2034 Common Stock 25,000 $ 0 25,000 (1) D
Stock Option (Right to Buy) $ 8.58 09/24/2026 A 25,000 09/24/2026 03/31/2035 Common Stock 25,000 $ 0 25,000 (1) D
Explanation of Responses:
1. As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.
/s/ Sandra Boenisch 09/28/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings